Capricor Therapeutics (NASDAQ:CAPR) issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04, Morningstar.com reports. The business had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.23 million. Capricor Therapeutics had a negative return on equity of 191.49% and a negative net margin of 909.76%.
NASDAQ:CAPR traded down $0.01 during mid-day trading on Friday, hitting $0.53. The company had a trading volume of 119,620 shares, compared to its average volume of 313,352. Capricor Therapeutics has a 1 year low of $0.31 and a 1 year high of $1.58. The firm has a market capitalization of $17.82 million, a PE ratio of -1.02 and a beta of 1.47.
Several research analysts recently weighed in on the company. Zacks Investment Research raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 21st. ValuEngine raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright cut their target price on Capricor Therapeutics from $8.60 to $3.50 and set a “buy” rating on the stock in a research report on Monday, December 31st. Finally, Maxim Group reaffirmed a “hold” rating on shares of Capricor Therapeutics in a research report on Wednesday, February 6th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $3.75.
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.